Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IBT Laboratories, a clinical-diagnostics and biomedical-research laboratory, has announced that it will launch a new pneumococcal antibody avidity test designed to help physicians better understand and manage their patients who have recurrent infections.
Subscribe to our email newsletter
Maureen Loftus, president of IBT, said: “IBT Laboratories was one of the first laboratories to develop a commercial pneumococcal assay to measure the concentration of antibodies produced in response to the pneumococcal vaccines -today, one of the most-widely prescribed tests used to determine why a patient has recurrent infections.
“Our new avidity test now lets the clinician assess the effectiveness of those antibodies. Together, these pneumococcal tests provide more insight into the strengths and weaknesses of a patient’s immune system.”